Bone hydatid disease
- 1Department of Orthopaedics, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Province, China
- 2Teaching Department, the First Affiliated Hospital of Xinjiang Medical University
- 3Xinjiang Hydatid Clinical Research Institute, the First Affiliated Hospital of Xinjiang Medical University
- Correspondence to: Dr Hao Wen Xinjiang Hydatid Clinical Research Institute, the First Affiliated Hospital of Xinjiang Medical University, No. 1, LiYuShan Road, Urumqi, Xinjiang Province 830054, China; wenh19{at}163.com
- Received 9 January 2007
- Accepted 6 March 2007
Abstract
Bone hydatid disease lacks a typical clinical appearance and image characteristics on x ray or CT are similar to those of tuberculosis, metastases and giant cell tumour or bone cysts. However, MRI does show distinctive diagnostic features of bone hydatid disease, especially in the spine. Until recently, treatment of osseous hydatid disease has been entirely surgical. Effective chemotherapy using benzimidazoles, particularly mebendazole, albendazole and combination treatments, has now been achieved in experimental studies and clinical practice. However, most of these drugs are still in the experimental stage or are in the early stages of clinical use.
- Alb-L, albendazole liposome
- AlbSO, albendazole sulfoxide
- AR, alveolar echinococcosis
- CE, cystic echinococcosis
- CIE, counterimmunoelectrophoresis
- CT, computed tomography
- EG, Echinococcus granulosus
- ELISA, enzyme-linked immunosorbent assay
- IHA, indirect haemagglutination
- MRH, magnetic resonance hydrography
- MRI, magnetic resonance imaging
- PMMA, polymethylmethacrylate
Footnotes
-
Conflict of interest: none stated
-
Patient consent to publish figures 2–7 was received.
